AI can accelerate discovery. It does not remove the formulation barrier
L'Oreal's GTC discussion shows AI moving deeper into formulation work, where delivery logic, product feel, and evidence still decide whether a candidate can become a real product.
AI can accelerate discovery. It does not remove the formulation barrier.
At NVIDIA GTC 2026, L’Oreal participated in a session on AI-enabled formulation optimization. The easy reading is that beauty R&D is becoming more AI-driven. The more important reading is that mature teams are placing AI inside a much heavier development system.
L’Oreal’s public discussion connected AI to patents, scientists, new formulas, testing, formulation complexity, consumer experience, and evidence. That sequence matters because candidate discovery is only one part of advanced skincare development.
If AI helps teams generate more candidate actives or formulation directions, the downstream bottleneck becomes more visible, not less important. A promising active still has to survive the formulation environment, reach the intended skin compartment, deliver an acceptable product feel, and support the claim being made.
For high-value topical actives, this is where partner decisions become more concrete. The question is not only whether a molecule looks promising on paper. It is whether the active can be matched with a delivery logic, formulation constraint set, application site, and evidence path that make product development feasible.
N1 Life’s peptide-enabled platform is built for that downstream layer: targeted skin delivery, formulation enhancement, and selective tissue penetration across multiple active types. The goal is not to replace formulation science with a faster front end, but to help promising actives move closer to usable product outcomes.
The industry signal is clear: AI may increase the number of things worth testing. It will also make the hard questions more expensive to ignore.